Founded in 2005, BioPharm’s clients include 17 of the world’s top 25 biopharma organizations. The agency brings deep expertise in omnichannel strategy, end-to-end media journey – spanning strategy, planning and operations, and data driven campaign execution -blending analytics, automation, and targeted engagement to deliver turnkey precision marketing solutions.

“BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships. This acquisition reinforces our position as the preferred tech-native, commercialization partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments”, said Manish Gupta, Chairman and CEO, Indegene. “I am delighted to welcome Steve and the BioPharm team to the Indegene family, and we look forward to shaping the future of AI-led commercialization together.”

“Indegene is a natural home for us, given their client-focused, innovation-first, employee-centric culture – backed by strong technology platforms, data and analytics capabilities, deep medical expertise, marquee client base and a global delivery model. And, we are very excited to join the larger Indegene family at a pivotal time for the industry”, said Steve Carickhoff, President, BioPharm. “Their life sciences-contextualized approach to AI will open up new possibilities, helping us deliver deeper value to clients. Together, we will push the boundaries of AI-powered pharma marketing worldwide – delivering more personalized, measurable, and patient-focused outcomes.”

Amid changing market dynamics, evolving regulatory complexities, and discerning HCP preferences in an AI-first era, more and more pharma companies are looking to transform their commercialization processes to make bold bets and be truly future-ready. However, traditional healthcare agencies of record are finding it difficult to deliver to pharma’s rapidly changing expectations. That’s why the industry is turning to specialized solution providers like Indegene, to co innovate future-ready commercialization models with an AI-first/data-driven approach.

This acquisition by Indegene is especially significant as many pharma companies have the twin agendas of managing mature and growth product portfolios and ramping up capabilities for new launches in an environment where physicians increasingly favor limited engagement models. These imperatives, along with the productivity agenda, are driving the adoption of innovative digital engagement approaches.

The post Indegene Announces Acquisition of BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Bengaluru, September 22, 2025: Datavant, the data collaboration platform trusted for healthcare, announced a strategic partnership with Indegene, a leading digital-first, life sciences commercialization company, today to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies. By embedding Datavant’s bespoke data enrichment capabilities into Indegene’s NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures, and more efficient recruitment processes for biopharmaceutical organizations.

Patient recruitment is one of the biggest hurdles in clinical development, particularly in rare diseases where eligible populations are small and dispersed. Datavant operates the nation’s largest health data retrieval network, spanning more than 80,000 hospitals and clinics and processing over 100 million patient records annually. Combined with Indegene’s suite of digitally powered solutions for clinical trial recruitment, the partnership streamlines the identification of suitable participants for studies based on specific health data criteria.

The result is more eligible participants have an opportunity to connect to the trials designed for their specific health conditions, including patients with rare and complex diseases. The partnership enables biopharma companies to reduce site-level screen failures, accelerate enrollment timelines, improve the screen-to-randomization ratios, and drive more informed decision-making.

“Rare diseases have long been defined by the impossibility of finding enough patients fast enough to bring new therapies to market,” said Arnaub Chatterjee, President and GM of Life Sciences of Datavant. “Together with Indegene, we are demonstrating how data enrichment solves that challenge today – and lays the foundation for a new model of clinical research in which sponsors can accelerate recruitment across even the most complex and hard-to-reach populations.”

“We are doubling down on enhancing our capabilities to deliver digital-first recruitment solutions for clients to transform clinical trial execution. Our partnership with Datavant is a key step in this journey,” said Ram Yeleswarapu, SVP, Enterprise Clinical Solutions at Indegene. “By integrating secure, real-time access to consented patient medical records into our screening process, we are minimizing one of the greatest challenges in clinical trials – screen failures at sites due to incomplete and ineffective pre-screening. This collaboration reinforces our positioning as the industry’s premier digital-first recruitment partner, empowering sponsors and sites with data-driven approaches that deliver measurable outcomes.”

The post Datavant and Indegene Partner to Power More Efficient Clinical Trial Recruitment appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

By leveraging the city’s highly skilled technology, management, and medical talent base, the company is enhancing its ability to help clients accelerate innovation, scale global operations, and deliver improved healthcare outcomes for patients worldwide.

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products. Its client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. Indegene has about 5,000 employees worldwide, 9 operations hubs and 20 offices across North America, Europe, and Asia.

The post Indegene Expands India Footprint, Opens New Center in Pune appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Indegene’s Europe-based clients can now benefit from this center as a strategic hub for consulting and commercialization solutions and modernize their operations with an AI-first approach. The company is strengthening its existing employee base in the region, with skillsets spanning a wide range of areas – consulting, creative, data and analytics, engineering and customer experience.

“London is a vital healthcare, technology and business innovation hub, with a great talent pool – making it an important market for life sciences companies in the region”, said Manish Gupta, Chairman and CEO, Indegene. “With our new center, we are better positioned to dial up innovation and engagement with our clients here and help them holistically improve their commercialization processes with an AI-first approach and stay ahead of the curve.”

Indegene launched a new entity in Spain last month. The company already has a significant presence in Europe, with centers in Germany, Ireland, and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities with teams spread across UK, Germany and US. In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. The world’s top 20 global biopharma companies, including many from Europe, trust Indegene for their commercialization needs.

The post Indegene Expands Presence in Europe, Announces New Center in London appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Indegene’s new Spain entity will serve as a key delivery hub for its Europe-based clients, helping them drive hyper-personalization and significantly elevate HCP and patient experience. The company is strengthening its already existing employee base in Spain, with capabilities in medical affairs, data and analytics, creative design, engineering, digital marketing and customer experience.

“Growing R&D investments, a thriving life sciences innovation ecosystem and a high-quality talent pool make Spain a vital market and talent hub for life sciences companies in Europe”, said Manish Gupta, Chairman and CEO, Indegene. “With our new entity in Spain, we can co-innovate and collaborate much better with clients, helping them use data and AI more effectively to modernize commercialization processes and fast-track business transformation.”

Indegene already has a significant presence in Europe, with centers in the UK, Germany, Ireland and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. Indegene supports many leading life sciences clients in the region in various ways across the commercialization value chain.

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products. It is one of the very few companies globally where a medical doctor and a data scientist work next to each other to solve big, impactful problems in life sciences. More than 20% of Indegene’s employees come from a medical education background and they work very closely with about 600 technologists, collaborating on advanced artificial intelligence (AI), machine learning (ML) and other technologies.

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. With over 5,000 employees worldwide, Indegene’s vast global footprint underscores its ability to scale and meet the evolving needs of the world’s leading pharma organizations across markets.

The post Indegene Expands Footprint in Europe, Launches New Entity in Spain appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

As the pharma industry faces increasing pressure to innovate and adapt, this new center will play a key role in helping companies accelerate their transformation. This move aligns with Indegene’s purpose: to enable healthcare organizations to be future-ready by combining deep medical expertise with fit-for-purpose technology.

India is rapidly emerging as a critical hub for global pharma companies, fueled by its vast pool of skilled medical and technology talent. These companies are increasingly seeking a partner with core domain expertise and life sciences-contextualized technology to help them scale their operations in a non-linear, technology-led way.

“Indegene has a strong track record in helping global pharma companies reimagine their commercialization processes, drive innovation with GenAI, and fully integrate these capabilities into their business processes,” said Manish Gupta, Chairman and CEO of Indegene. “With the new center, we are further strengthening our capabilities to help life sciences companies modernize and transform their commercial, medical and clinical operations, with our fit-for-purpose technology.”

Indegene’s leadership in life sciences commercialization has been further recognized by the Everest Group, which named the company a Leader in its Life Sciences Digital Services Specialist PEAK Matrix^® Assessment 2024. Additionally, HFS Research recently recognized Indegene as a Leader in GenAI in Life Sciences, further validating the latter’s ongoing commitment to innovation and excellence in the industry.

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. This vast global footprint underscores Indegene’s ability to scale and meet the evolving needs of the world’s leading pharma organizations across markets.

The post Indegene Expands Global Delivery Network, Announces A New Center In Hyderabad  appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

• Achieved revenue of INR 6,765 million in Q1FY25 with growth of 11.4% vs Q1FY24
• Robust EBITDA growth of 14.5% in Q1FY25 vs Q1FY24
• Became a zero-debt company        (in INR Mn)

Notes:

1. Based on average exchange rate of ₹83.4 per USD for quarter ended June 30, 2024, ₹83.0 per USD for quarter ended March 31, 2024, and ₹82.2 per USD for quarter ended June 30, 2023, respectively.
2. Based on INR revenue. YoY growth for quarter June 30, 2023, based on unaudited financials.
3. Earnings before interest, taxes, depreciation and amortization (“EBITDA”) represents profit/(loss) for the period before income tax expense, finance costs, depreciation and amortization expense, interest income and any exceptional items.

“In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients with increased activity and volume levels tracking the larger pipeline of impending new product launches”, said Manish Gupta, Chairman and CEO, Indegene Limited. “Based on our conversations with our top clients, we anticipate similar momentum across the industry. Further, compared to last year, our pipeline is heathier and the quality of conversations with clients is much better, which gives us confidence about driving robust growth in the medium term.”

“Our Q1FY25 EBITDA margin of 19.6% and PAT margin of 13.0% is an improvement of 50 bps and 170 bps vs Q1FY24. Indegene is now a zero-debt company with repayment of loans, and we anticipate the financial leverage to drive stronger PAT growth going forward”, said Suhas Prabhu, CFO, Indegene Limited. “Also, we continue to strengthen our technology and automation initiatives, which we believe will have a positive impact on the margin in the future. Further, we anticipate that the EBITDA margin would have a similar trajectory as FY24 with a stronger H2 compared to H1.”

The post Indegene reports robust profit growth for Q1FY25 appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.